Jongkatkorn Chaowasaporn, Luvira Vor, Suwanprinya Chalisa, Piampatipan Kantaruthai, Leeratanakachorn Natwutpong, Tipwaratorn Theerawee, Titapun Attapol, Srisuk Tharatip, Theeragul Suapa, Jarearnrat Apiwat, Thanasukarn Vasin, Pugkhem Ake, Khuntikeo Narong, Pairojkul Chawalit, Kamsa-Ard Supot, Bhudhisawasdi Vajarabhongsa
Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
Department of Surgery, Saraburi Hospital, Saraburi 18000, Thailand.
World J Gastrointest Surg. 2023 Mar 27;15(3):362-373. doi: 10.4240/wjgs.v15.i3.362.
Enhanced recovery after surgery (ERAS) program has been proved to improve postoperative outcome for many surgical procedures, including liver resection. There was limited evidence regarding the feasibility and benefit of ERAS in patients who underwent liver resection for cholangiocarcinoma.
To evaluate the feasibility of ERAS in patients who underwent liver resection for cholangiocarcinoma and its association with patient outcomes.
We retrospectively analyzed 116 cholangiocarcinoma patients who underwent hepatectomy at Srinagarind Hospital, Khon Kaen University between January 2015 and December 2016. The primary outcome was the compliance with ERAS. To determine the association between ERAS compliance and patient outcomes. the patients were categorized into those adhering more than and equal to 50% (ERAS ≥ 50), and below 50% (ERAS < 50) of all components. Details on type of surgical procedure, preoperative and postoperative care, tumor location, postoperative laboratory results, and survival time were evaluated. The compliance with ERAS was measured by the percentage of ERAS items achieved. The Kaplan-Meier curve was used for survival analysis.
The median percentage of ERAS goals achieved was 40% (± 12%). Fourteen patients (12.1%) were categorized into the ERAS ≥ 50 group, and 102 patients were in the ERAS < 50 group. Postoperative hospital stay was significantly shorter in the ERAS ≥ 50 group [8.9 d, 95% confidence interval (CI): 7.3-10.4 d] than in the ERAS < 50 group (13.7 d, 95%CI: 12.2-15.2 d) ( = 0.0217). No hepatobiliary-related complications or in-hospital mortality occurred in the ERAS ≥ 50 group. Overall survival was significantly higher in the ERAS ≥ 50 group. The median survival of the patients in the ERAS < 50 group was 1257 d (95%CI: 853.2-1660.8 d), whereas that of the patients in the ERAS ≥ 50 group was not reached.
Overall ERAS compliance for patients who underwent liver resection for cholangiocarcinoma is poor. Greater ERAS compliance could predict in-hospital, short-term, and long-term outcomes of the patients.
手术加速康复(ERAS)方案已被证明可改善包括肝切除术在内的多种外科手术的术后结局。关于ERAS在接受胆管癌肝切除术患者中的可行性和益处的证据有限。
评估ERAS在接受胆管癌肝切除术患者中的可行性及其与患者结局的关联。
我们回顾性分析了2015年1月至2016年12月期间在孔敬大学诗里拉吉医院接受肝切除术的116例胆管癌患者。主要结局是对ERAS的依从性。为了确定ERAS依从性与患者结局之间的关联,将患者分为所有组成部分依从性超过和等于50%(ERAS≥50)以及低于50%(ERAS<50)的两组。评估了手术方式、术前和术后护理、肿瘤位置、术后实验室检查结果及生存时间的详细情况。通过实现的ERAS项目百分比来衡量对ERAS的依从性。采用Kaplan-Meier曲线进行生存分析。
实现的ERAS目标的中位数百分比为40%(±12%)。14例患者(12.1%)被归入ERAS≥50组,102例患者在ERAS<50组。ERAS≥50组的术后住院时间显著短于ERAS<50组[8.9天,95%置信区间(CI):7.3 - 10.4天](ERAS<50组为13.7天,95%CI:12.2 - 15.2天)(P = 0.0217)。ERAS≥50组未发生肝胆相关并发症或院内死亡。ERAS≥50组的总生存率显著更高。ERAS<50组患者的中位生存期为1257天(95%CI:853.2 - 1660.8天),而ERAS≥50组患者的中位生存期未达到。
接受胆管癌肝切除术患者的总体ERAS依从性较差。更高的ERAS依从性可预测患者的院内、短期和长期结局。